

DAFTAR PUSTAKA

- Ahuja, S. and Dong, M.W. 2005, *Handbook of Pharmaceutical Analysis by HPLC, Separation Science and Technology*, Vol. 6, 1st edition, Elsevier Academic Press, London, UK, pp 19-45, 203-204.
- Ahuja, S. and Rasmussen, H. 2007, *HPLC Method Development for Pharmaceuticals*, Vol. 8, Elsevier Academic Press, London, UK, pp 452-455.
- Angel, M.J.R. and Berthod, A. 2006, Analytical Techniques for Furosemide Determination, *Sep. Purif. Rev.*, **35**:39–58.
- Bansal, T., Singh, M., Mishra, G., Talegaonkar, S., Khar, R.K., Jaggi, M. and Mukherjee, R. 2007, Concurrent Determination of Topotecan and Model Permeability Markers (Atenolol, Antipyrine, Propranolol, and Furosemide) by Reversed Phase Liquid Chromatography: Utility in Caco-2 Intestinal Absorption Studies, *J. Chromatogr. B.*, **859**:261–266.
- Bosch, M.E., Sanchez, A.J.R., Rojas, F.S. and Ojeda, C.B. 2008, Recent Development in Analytical Determination of Furosemide, *J. Pharm. Biomed. Anal.*, **48**:519–532.
- BP, 2009, *British Pharmacopoeia 2009*, British Pharmacopoeia Commission, London, UK.
- BPOM, 2004, *Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor HK.00.05.3.1818 tentang Pedoman Uji Bioekivalensi*, Badan Pengawas Obat dan Makanan Republik Indonesia, Jakarta.
- BPOM, 2011, *Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor HK.03.1.23.12.11.10217 tentang Obat Wajib Uji Ekivalensi*, Badan Pengawas Obat dan Makanan Republik Indonesia, Jakarta.
- Bragatto, M.S., Santos, M.B.D., Pinto, A.M.P., Gomes, E., Angonese, N.T., Viezzer, W.F.G., Donaduzzi, C.M. and Manfio, J.L. 2011, Comparison between Pharmacokinetic and Pharmacodynamic of Single-Doses of Furosemide 40 mg Tablets, *J. Bioequiv. Bioavail.*, **3(8)**:191-197.

- Chan, C.C., Lam, H., Lee, Y.C. and Zang, X.M. 2004, *Analytical Method Validation and Instrument Performance Verification*, John Wiley & Sons, Inc, Canada, pp 21, 109-110.
- El-Saharty, Y.S. 2003, Simultaneous High Performance Liquid Chromatography Assay of Furosemide and Propranolol HCl and Its Application in a Pharmacokinetic Study, *J. Pharm. Biomed. Anal.*, **33**:699–709.
- EMA, 2011, *Guideline on Bioanalytical Method Validation*, European Medicine Agency, UK.
- Ermer, J. and Miller, H.M. 2005, *Method Validation in Pharmaceutical Analysis. A Guide To Best Practice*, 1st edition, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 101-119.
- FDA, 1994, *Validation of Chromatographic Method*, Center for Drug Evaluation and Research, Rockville.
- FDA, 2001, *Guidance for Industry: Bioanalytical Method Validation*, Departemen of Health and Human Services, USA.
- Gandjar, I.G. and Rohman, A. 2007, *Kimia Farmasi Analisis*, Pustaka Pelajar, Yogyakarta, pp 31-36.
- Gandjar, I.G. and Rohman, A. 2012, *Analisis Obat Secara Spektroskopi dan Kromatografi*, Pustaka Pelajar, Yogyakarta, pp 468-488.
- Grabic, R., Fick, J., Lindberg, R.H., Fedorova, G. and Tysklind, M. 2012, Multi-residue Method for Trace Level Determination of Pharmaceuticals in Environmental Samples Using Liquid Chromatography Coupled to Triple Quadrupole Mass Spectrometry, *Talanta*, **100**:183–195.
- Hamid, A. 2000, High Performance Liquid Chromatography-Mass Spectrometric Analysis of Furosemide in Plasma and its Use in Pharmacokinetic Studies, *Il Pharmaco*, **55**:448–454.
- Harmita, 2004, Petunjuk Pelaksanaan Validasi Metode dan Cara Perhitungannya, *Majalah Ilmu Kefarmasian*, **1**(3):117-135.

- ICH, 2005, *Validation of Analytical Procedures: Text and Methodology Q2 (R1)*, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
- Kazakevich, Y. and LoBrutto, R. 2007, *HPLC for Pharmaceutical Scientists*, John Wiley & Sons, Hoboken, New Jersey, pp 6-14.
- Kemenkes, 2014, *Farmakope Indonesia*, 5th edition, Kementerian Kesehatan Republik Indonesia, Jakarta, Indonesia, pp 468-469.
- Knauf, H. and Mutschler, E. 1998, Clinical Pharmacokinetics and Pharmacodynamics of Torasemide, *Clin Pharmacokinet.*, **1**(34):1–24.
- Kromidas, S. 2004, *Practical Problem Solving in HPLC*, Wiley-VCH, Weinheim, Germany, pp 13-14, 108-112.
- Meyer, V.R. 2004, *Practical High-Performance Liquid Chromatography*, 4th edition, Wiley & Sons, Chichester, UK, pp 82-99.
- Miller, J.M. 2005, *Chromatography: concepts and contrasts*, 2nd edition, John Wiley & Sons, Hoboken, New Jersey, pp 194-259.
- Miller, J.N. and Miller, J.C. 2005, *Statistics and Chemometrics for Analytical Chemistry*, Pearson Education, Harlow, England, pp 18-69.
- Moffat, A.C., Osselton, D., Widdop, B., Watts, J. and Galichet, L.V. 2011, *Clarke's Analysis of Drugs and Poisons: In Pharmaceuticals, Body Fluid and Postmortem Material*, Pharmaceutical Press, London, United Kingdom, pp 749, 1448-1449, 1974-1976.
- Mojtahedzadeh, M., Ardakani, M.T., Salehifar, E., Najafi, A., Khajavi, M.R., Moeini, M. and Sadray, S. 2005, The Relationship Between Pharmacokinetic Variables and Pharmacodynamic Profiles of Bolus Versus Continuous Infusion of Furosemide in Critically Ill Patients, *DARU*, **3**(13):127–132.
- Neal, M.J. 2002, *Medical Pharmacology at a Glance*, 4th edition, Blackwell Science Ltd., United Kingdom, pp 34-35.

- Novak, K.T., Szoke, V., Volgy, G., Horvath, P., Ambrus, R. and Revesz, P.S. 2013, Biorelevant Solubility of Poorly Soluble Drugs: Rivaroban, Furosemide, Papaverine, and Niflumic Acid, *J. Pharm. Biomed. Anal.*, **83**:279–285.
- Shapiro, S. and Wilk, M.B. 1965, An Analysis of Variance Test for Normality (Complete Samples), *Biometrika*, **52**:591–611.
- Shargel, L. and Yu, A.B.C. 1988, *Biofarmasetika dan Farmakoterapi Terapan*, 2nd edition, Airlangga University Press, Surabaya, pp 96-100, 167-169, 181-189.
- Snyder, L.R., Kirkland, J.J. and Dolan, J.W. 2010, *Introduction to Modern Liquid Chromatography*, 3rd ed, Wiley & Sons, Hoboken, New Jersey, pp 253-331, 531-553.
- Snyder, L.R., Kirkland, J.J. and Glajch, J.L. 1997, *Practical HPLC Method Development*, 2nd ed, John Wiley & Sons, Hoboken, New Jersey, pp 60-70.
- Sora, D.I., Udrescu, S., Albu, F., David, V. and Medvedovici, A. 2010, Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples, *J. Pharm. Biomed. Anal.*, **52**:734–740.
- Stockley, I. 2008, *Drug Interactions*, 8th edition, Pharmaceutical Press, London, United Kingdom, pp 4, 39.
- Sugiyono, 2012, *Statistika untuk Penelitian*, Alfabeta, Bandung, pp 75-83, 117-163.
- Sweetman, S.C. 2009, *Martindale The Complete Drug Reference*, 36th edition, Pharmaceutical Press, London, United Kingdom, pp 1292-1295.
- Syukri, Y. and Sukmawati, U. 2004, Desintegrasi dan Disolusi Tablet Furosemid dari Berbagai Produk Generik dan Produk Paten yang Beredar, *Logika*, **1**(1):65-73.
- UNODC, 2009, *Guidance for The Validation of Analytical Methodology and Calibration of Equipment used for testing of Illicit Drugs in Seized Materials and Biological Specimens*, United Nations Office on Drugs and Crime, New York.

USP, 2006, *United States Pharmacopoeia No. 30 - National Formulary No. 25*,
United States Pharmacopeial Convention, United States America.

Walash, M., El-Enany, N., Eid, M. and Fathy, M. 2012, Micellar High Performance Liquid Chromatographic Determination of Furosemide and Spironolactone in Combined Dosage Forms: Application to Human Plasma, *J. Pharm. Res.*, **5**(5):2648-2656.

Walse, M., Kelly, M.T. and Smyth, M.R. 1996, Comparison of Two Extraction Methods for Determination of Propranolol and Furosemide in Human Plasma by Mixed-Mode Chromatography. *J. Pharm. Biomed. Anal.*, **14**:475–481.

Wells, B.G., Dipiro, J.T., Schiwinghammer, T.L. and Dipiro, C.V. 2009, *Pharmacotherapy Handbook*, 7th edition, McGraw-Hill Companies Inc., United States, pp 85, 91, 116, 246, 882, 884, 894.

Youm, I. and Youan, B.C. 2013, Validated Reverse-Phase High Performance Liquid Chromatography for Quantification of Furosemide in Tablets and Nanoparticles, *J. Analyt. Meth. Chem.*, **2013**:1–9.